Vericel is a provider in cell therapies and specialty biologics for the sports medicine and severe burn care markets. Co.'s products include: MACI, which is an autologous implant for the repair of symptomatic, full-thickness cartilage defects of the knee in adult patients; and Epicel, which is a permanent skin replacement for adult and pediatric patients with deep dermal or full-thickness burns greater than or equal to 30% of total body surface area. Both products are marketed in the U.S. In addition, Co. holds license to commercialize NexoBrid, which is used for debridement of severe thermal burns. The VCEL stock yearly return is shown above.
The yearly return on the VCEL stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2015 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the VCEL annual return calculation with any dividends reinvested as applicable (on ex-dates).
|